A Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety
The primary efficacy endpoint is the mean change from Baseline to EOT in total CDRS-R (raw) score.
The secondary efficacy endpoints include:
Safety endpoints include:
Inclusion Criteria:
Exclusion Criteria:
jessica.ferrigno@bauschhealth.com520-246-8205